Back to search
FDAFDA · Food and drugs·Recall number D-0366-2022

Metformin 750 mg Extended Release NDC # 70518-2920-00

Published January 19, 2022 · Recall initiated: December 30, 2021

Summary

FDA records drug Class II recall D-0366-2022, published January 19, 2022 and initiated December 30, 2021. Recalling firm: RemedyRepack Inc.; Status: Terminated; Reported quantity: 56 Blister Cards; Lot: Lot # J0511265-021121, exp. date 02/28/2022 J0499451-122220, exp. date 01/31/2022 J0496563-120820, exp. date 12/31/2021 J0495111-120120, exp. date 12/31/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RemedyRepack Inc.
Distributor
Product was distributed to one direct account in PA.
Lot
Lot # J0511265-021121, exp. date 02/28/2022 J0499451-122220, exp. date 01/31/2022 J0496563-120820, exp. date 12/31/2021 J0495111-120120, exp. date 12/31/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metformin 750 mg Extended Release NDC # 70518-2920-00 recalled?

Yes. FDA published recall D-0366-2022 on January 19, 2022. Reported hazard: CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter